SCHEMBL2117478

SCHEMBL2117478

Cc1ccc(-c2cccs2)cc1NS(=O)(=O)c1cccnc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GHSR Q92847 1/20 0.50
ALDH1A1 P00352 3/20 0.48
MAPT P10636 3/20 0.48
KMT2A Q03164 2/20 0.48
KDM4E B2RXH2 2/20 0.48
MEN1 O00255 1/20 0.48
ACLY P53396 2/20 0.47
HDAC3 O15379 2/20 0.47
HDAC1 Q13547 2/20 0.47
HDAC2 Q92769 2/20 0.47
SLC40A1 Q9NP59 4/20 0.47
CYP2E1 P05181 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2A6 P11509 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2B6 P20813 1/20 0.46
GLO1 Q04760 1/20 0.44
CKS1B P61024 2/20 0.43
SKP2 Q13309 2/20 0.43
PIK3CA P42336 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2119666 0.88 GHSR (0.56) GHSRALDH1A1MAPTKMT2AKDM4E
SCHEMBL2119636 0.86 GHSR (0.52) GHSRALDH1A1MAPTKMT2AKDM4E
SCHEMBL2119624 0.85 SLC40A1 (0.47) ALDH1A1MAPTKMT2AKDM4ESLC40A1
SCHEMBL2117057 0.84 GHSR (0.46) GHSRALDH1A1MAPTKMT2AKDM4E
SCHEMBL2118227 0.83 GHSR (0.47) GHSRALDH1A1MAPTKMT2AKDM4E
SCHEMBL2121413 0.82 GHSR (0.50) GHSRALDH1A1MAPTKMT2AKDM4E
SCHEMBL2118481 0.81 GHSR (0.49) GHSRALDH1A1MAPTKMT2AKDM4E
SCHEMBL2122153 0.80 GHSR (0.58) GHSRALDH1A1MAPTKMT2AKDM4E
SCHEMBL2119048 0.80 GHSR (0.58) GHSRALDH1A1MAPTKMT2AKDM4E
SCHEMBL2117751 0.80 GHSR (0.58) GHSRALDH1A1MAPTACLYSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095012-A1 TOLUIDINE SULFONAMIDES AND THEIR USE ELARA PHARMACEUTICALS GMBH (DE) 2012-04-19 US disclosed
EP-2382190-A1 TOLUIDINE SULFONAMIDES AND THEIR USE AS-INHIBITORS European Molecular Biology Laboratory (EMBL) (DE) 2011-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095012-A1 TOLUIDINE SULFONAMIDES AND THEIR USE HIF1A, HIF1AN, EGLN3 GHSR 1390/4885ALDH1A1 1063/4885MAPT 4747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.